MA53739A - Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés - Google Patents

Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés

Info

Publication number
MA53739A
MA53739A MA053739A MA53739A MA53739A MA 53739 A MA53739 A MA 53739A MA 053739 A MA053739 A MA 053739A MA 53739 A MA53739 A MA 53739A MA 53739 A MA53739 A MA 53739A
Authority
MA
Morocco
Prior art keywords
parkinson
disease
treatment
composition
related disorders
Prior art date
Application number
MA053739A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA53739A publication Critical patent/MA53739A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053739A 2018-09-25 2019-09-24 Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés MA53739A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862735997P 2018-09-25 2018-09-25
US201862785606P 2018-12-27 2018-12-27
US201862785605P 2018-12-27 2018-12-27
US201862785602P 2018-12-27 2018-12-27
US201962787614P 2019-01-02 2019-01-02
US201962817274P 2019-03-12 2019-03-12
US201962840539P 2019-04-30 2019-04-30

Publications (1)

Publication Number Publication Date
MA53739A true MA53739A (fr) 2021-12-29

Family

ID=69949689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053739A MA53739A (fr) 2018-09-25 2019-09-24 Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés

Country Status (11)

Country Link
US (1) US20210338652A1 (fr)
EP (1) EP3856168A4 (fr)
JP (1) JP2022502479A (fr)
KR (1) KR20210107621A (fr)
CN (1) CN113164424A (fr)
AU (1) AU2019346543A1 (fr)
BR (1) BR112021008087A2 (fr)
CA (1) CA3121184A1 (fr)
IL (1) IL282562A (fr)
MA (1) MA53739A (fr)
WO (1) WO2020068832A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3065670T3 (en) 2017-04-24 2026-05-07 Alto Neuroscience Inc Compositions and method for treating depression
CN111588692B (zh) * 2020-05-23 2022-11-22 常州市第四制药厂有限公司 盐酸普拉克索口服溶液
EP4385497A1 (fr) * 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron
WO2024126408A1 (fr) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Association de dose fixe sans antioxydant de netupitant et de palonosétron
EP4385500A1 (fr) * 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Combinaison de doses fixes comprenant du nétupitant et du palonosétron
KR20250125376A (ko) 2022-12-12 2025-08-21 알프레드 이. 티펜바흐어 게엠베하 운트 & 코. 카게 네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0942732B1 (fr) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies
JP2004523543A (ja) * 2001-02-15 2004-08-05 ニューロサーチ、アクティーゼルスカブ 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法
AU2015213396B2 (en) * 2009-09-18 2018-02-15 Chase Pharmaceuticals Corporation Method and composition for treating Alzheimer-type dementia
EP2651357B1 (fr) * 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Films sublinguaux
US20150297509A1 (en) * 2012-11-19 2015-10-22 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions and methods of treatment thereof
WO2018039159A1 (fr) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Combinaison d'antagoniste de m2 muscarinique
EP3600291A4 (fr) * 2017-03-27 2020-12-23 Chase Therapeutics Corporation Compositions et méthodes de traitement des synucléinopathies
IL271464B2 (en) * 2017-06-30 2024-08-01 Chase Therapeutics Corp NK-1 antagonist compositions and methods for use in the treatment of depression

Also Published As

Publication number Publication date
EP3856168A4 (fr) 2022-07-06
AU2019346543A1 (en) 2021-05-20
KR20210107621A (ko) 2021-09-01
CN113164424A (zh) 2021-07-23
EP3856168A1 (fr) 2021-08-04
US20210338652A1 (en) 2021-11-04
IL282562A (en) 2021-06-30
CA3121184A1 (fr) 2020-04-02
JP2022502479A (ja) 2022-01-11
BR112021008087A2 (pt) 2021-08-03
WO2020068832A1 (fr) 2020-04-02

Similar Documents

Publication Publication Date Title
EP3856168A4 (fr) Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
EP3856478A4 (fr) Formulations pour le traitement de la maladie de l'oeil sec
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3837359A4 (fr) Méthodes et compositions pour le traitement d'une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3820537A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP3852735A4 (fr) Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3737361A4 (fr) Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie
EP3924371A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP3927706A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles prolifératifs
EP3810142A4 (fr) Thérapies anti-rétrovirales et inhibiteurs de la transcriptase inverse pour le traitement de la maladie d'alzheimer
EP3883554A4 (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
EP3906043A4 (fr) Procédés et compositions pour le traitement de la maladie de fabry
EP3655404A4 (fr) Composés et leur utilisation pour le traitement d'infections microbiennes
EP3752196A4 (fr) Domaines variants de liaison à cd3 et leur utilisation en polythérapies pour le traitement d'une maladie
EP3802568A4 (fr) Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés
MA55141A (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
EP3852722A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer